What we do Jagsonpal Pharmaceuticals Ltd manufactures and markets pharmaceuticals concentrating on gynecology, orthopedics, dermatology, and childcare medicines in India. |
Founded in 1,978 |
Market share Among top players in niche therapies with multiple number 1 and top 5 ranked brands in India. |
Problem solved Provides effective treatments for chronic and sub-chronic conditions in women’s health, orthopedics, pediatrics, and dermatology. |
Top clients or who we serve Serves healthcare professionals and patients across India, focusing on B2B with doctors and hospitals. |
Key management Manish Gupta, Managing Director and CEO. |
Our journey and innovations Founded in 1978, expanded through alliances and acquisitions; launched innovative products like Lycored bioactive and acquired Yash Pharma business in 2024. |
Where we operate Operates pan-India with products also marketed in Southeast Asia. |
Top products or what we offer Key offerings include branded generics and OTC drugs in gynecology, orthopedics, dermatology, pediatrics. |
Top brands Indocap (#1 in osteoarthritis), Indocap SR, Metadec, Endoreg, Lycored Plus (natural antioxidant). |
Raw materials needed Pharmaceutical raw materials sourced via contract manufacturing organizations. |
Raw materials supplier Collaborates with established CMOs conforming to WHO-GMP standards. |
Recurring vs cyclical contribution Revenues primarily recurring through steady medicine demand and brand loyalty. |
Our industry position Ranked #8 in Indian pharma corporate value; niche market leadership in multiple drug categories. |
Financial highlights FY25 revenue ₹268.7 Cr, net profit ₹55.4 Cr; 9MFY26 revenue ₹223 Cr with 6% YoY growth, robust margin expansion. |
Geographical revenue split Revenue primarily from Indian market with some Southeast Asia exposure. |
Order book - |
Whats driving growth Growth driven by new product launches, strategic acquisitions, brand equity, and expanding market reach. |
Our future plans Focus on launching 4-6 products annually, expanding sales force, and integrating acquisitions for scale. |
Our green promise Committed to CSR focused on women’s health, sanitation, and community well-being. |
Our people and values Employs 1410 staff, fostering inclusive culture with compliance to labor laws and zero-tolerance for harassment. |
Key challenges ahead Competition from pharma majors and regulatory changes in healthcare sector. |
Interesting facts First brand Indocap crossed ₹50 Cr sales; strong foothold in sub-chronic therapy segments. |
Risks and strategy Mitigates risks via product diversification, strategic R&D, acquisitions, and strong governance. |
